サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1388197

痛風治療薬市場、シェア、市場規模、動向、産業分析レポート：薬剤クラス別、病状別、地域別、セグメント別予測、2023年～2032年

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
痛風治療薬市場、シェア、市場規模、動向、産業分析レポート：薬剤クラス別、病状別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年10月23日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris market researchの最新調査によると、痛風治療薬の世界市場規模は2032年までに60億4,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

生物製剤は、再生療法に焦点を当てた研究開発が増加し、受け入れが増加しています。これらの革新的な治療アプローチは、痛風の症状や根本的な原因に対処する上で大きな可能性を示しています。さらに、画像診断モダリティの著しい進歩により、痛風の効果的な診断およびモニタリング能力が向上しています。

さらに、痛風という病気とその危険因子に対する理解が深まったことで、医療専門家や患者の意識も高まっています。痛風は主に血中の尿酸値が高い40歳以上の男性に発症します。男性は女性に比べ痛風を発症しやすいです。過剰な尿酸は針状の結晶の形成につながり、関節痛、炎症、痛みを引き起こします。

これらの複合的な要因が、効果的な痛風治療薬の需要を促進しています。製薬会社や研究者は、痛風の症状や長期的な管理に対処するため、新しく改良された治療法の開発に積極的に取り組んでいます。その目的は、痛みを和らげ、炎症を抑え、痛風発作の再発を予防する標的療法を患者に提供することです。

痛風はライフスタイルの変化や食生活の要因により世界的に増加しており、患者数は拡大しています。市場は、新薬の処方や組み合わせなど、治療オプションの進歩を目の当たりにしており、有効性と利便性の向上を提供しています。

さらに、個々の患者の特性に基づいて治療法を調整する個別化医療のアプローチも普及しつつあります。認知度と診断率の上昇、技術の進歩、新興市場での拡大が市場の成長にさらに貢献しています。また、痛風治療薬の研究開発は、業界主要企業間の提携や協力関係によって促進されています。

痛風治療薬市場レポートハイライト

非ステロイド性抗炎症薬（NSAIDs）分野が最も高いシェアで市場を独占。非ステロイド性抗炎症薬（NSAIDs）は、広く入手可能であり、費用対効果に優れ、重度の痛風発作時に有効であることから、リウマチ性疾患および非リウマチ性疾患における炎症および疼痛を軽減する第一選択薬として好まれています。

慢性セグメントは市場で最大の売上シェアを占めると予想されます。このセグメントの成長は、様々な尿酸降下薬のイントロダクションと、新たな治療薬が市場に参入する可能性によって促進されています。

北米が市場を独占しており、予測期間中もその優位性を維持する意向です。痛風は北米で多くの人々に影響を及ぼしており、米国だけでも830万人が罹患していると推定され、有病率は1%～4%です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の痛風治療薬市場に関する洞察

  • 痛風治療薬市場- 業界スナップショット
  • 痛風治療薬市場力学
    • 促進要因と機会
      • 世界中で痛風の有病率が増加
      • 継続的な研究開発活動
    • 抑制要因と課題
      • 治療費
  • PESTLE分析
  • 痛風治療薬業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の痛風治療薬市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • 非ステロイド性抗炎症薬（NSAIDs）
  • コルチコステロイド
  • コルヒチン
  • 尿酸降下剤

第6章 世界の痛風治療薬市場、病状別

  • 主な調査結果
  • イントロダクション
  • 急性
  • 慢性

第7章 世界の痛風治療薬市場、地域別

  • 主な調査結果
  • イントロダクション
    • 痛風治療薬市場評価、地域別、2019-2032年
  • 痛風治療薬市場-北米
    • 北米：痛風治療薬市場、病状別、2019-2032年
    • 北米：痛風治療薬市場、薬剤クラス別、2019-2032年
    • 痛風治療薬市場-米国
    • 痛風治療薬市場- カナダ
  • 痛風治療薬市場- 欧州
    • 欧州：痛風治療薬市場、病状別、2019～2032年
    • 欧州：痛風治療薬市場、薬剤クラス別、2019～2032年
    • 痛風治療薬市場- 英国
    • 痛風治療薬市場- フランス
    • 痛風治療薬市場- ドイツ
    • 痛風治療薬市場- イタリア
    • 痛風治療薬市場- スペイン
    • 痛風治療薬市場- オランダ
    • 痛風治療薬市場- ロシア
  • 痛風治療薬市場- アジア太平洋
    • アジア太平洋：痛風治療薬市場、病状別、2019～2032年
    • アジア太平洋：痛風治療薬市場、薬剤クラス別、2019～2032年
    • 痛風治療薬市場- 中国
    • 痛風治療薬市場- インド
    • 痛風治療薬市場- マレーシア
    • 痛風治療薬市場- 日本
    • 痛風治療薬市場- インドネシア
    • 痛風治療薬市場- 韓国
  • 痛風治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：痛風治療薬市場、病状別、2019～2032年
    • 中東およびアフリカ：痛風治療薬市場、薬剤クラス別、2019～2032年
    • 痛風治療薬市場- サウジアラビア
    • 痛風治療薬市場- アラブ首長国連邦
    • 痛風治療薬市場- イスラエル
    • 痛風治療薬市場- 南アフリカ
  • 痛風治療薬市場-ラテンアメリカ
    • ラテンアメリカ：痛風治療薬市場、病状別、2019-2032年
    • ラテンアメリカ：痛風治療薬市場、薬剤クラス別、2019-2032年
    • 痛風治療薬市場- メキシコ
    • 痛風治療薬市場- ブラジル
    • 痛風治療薬市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Ablynx
  • Antares Pharma
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Horizon Pharma
  • JW Pharmaceutical
  • LG Life Sciences
  • Merck
  • Novartis
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • Sandoz（a subsidiary of Novartis）
  • Sanofi
  • Takeda Pharmaceuticals
  • Teijin Pharma
  • Vertex Pharmaceuticals
図表

List of Tables

  • Table 1 Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 2 Global Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 3 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 5 North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 7 U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 8 Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 9 Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 10 Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 11 Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 13 UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 14 France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 15 France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 16 Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 17 Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 19 Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 20 Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 21 Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 25 Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 28 China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 29 China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 31 India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 34 Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 35 Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 38 South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 39 South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 44 UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 45 UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 46 Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 47 Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 49 South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 50 Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 51 Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 52 Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 53 Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 55 Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 56 Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • Table 57 Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Gout Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Disease Condition
  • Figure 7 Global Gout Therapeutics Market, by Disease Condition, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Drug Class
  • Figure 9 Global Gout Therapeutics Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10 Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Gout Therapeutics Market
目次
Product Code: PM1611

The global gout therapeutics market size is expected to reach USD 6.04 billion by 2032, according to a new study by Polaris market research. The report "Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents); By Disease Condition; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biologics has a rising acceptance and increased research and development focused on regeneration therapies. These innovative treatment approaches show great promise in addressing gout's symptoms and underlying causes. Additionally, there have been significant advancements in imaging modalities, which have enhanced the ability to diagnose and monitor gout effectively.

Furthermore, a greater understanding of the disease and its risk factors leads to increased awareness among healthcare professionals and patients. Gout primarily affects men over 40 with high uric acid levels in their blood. Males are more susceptible to developing gout compared to females. Excessive uric acid leads to the formation of needle-like crystals, which can result in joint pain, inflammation, and soreness.

These combined factors have propelled the demand for effective gout therapeutics. Pharmaceutical companies and researchers are actively working to develop new and improved treatment options to address the symptoms and long-term management of gout. The aim is to provide patients with targeted therapies that alleviate pain, reduce inflammation, and prevent recurrent gout attacks.

Gout is growing globally due to lifestyle changes and dietary factors, expanding the patient pool. The market is witnessing advancements in treatment options, including new drug formulations and combinations, offering improved efficacy and convenience.

Additionally, personalized medicine approaches are gaining traction, tailoring treatments based on individual patient characteristics. Rising awareness and diagnosis rates, technological advancements, and expansion in emerging markets further contribute to the market's growth. Collaborations and partnerships among key industry players also facilitate research and development efforts in gout therapeutics.

Gout Therapeutics Market Report Highlights

NSAIDs segment dominated the market with highest share. Due to their widespread availability, cost-effectiveness, and efficacy during severe gout attacks, NSAIDs are the preferred first-line treatment for reducing inflammation and pain in rheumatic and non-rheumatic diseases.

Chronic segment anticipated to hold the largest revenue share of the market. The growth of this segment is fueled by the introduction of various urate-lowering drugs and the potential for new treatments to enter the market.

North America dominated the market and willing to maintain its dominance over the forecast period. Gout affects many people in North America, with an estimated 8.3 million individuals affected in the United States alone and a prevalence rate ranging from 1% to 4%.

The global key market players include: Ablynx, Antares Pharma, CymaBay Therapeutics, Astellas Pharma, AstraZeneca, Horizon Pharma, Boehringer Ingelheim, Merck, Eisai, Regeneron Pharmaceuticals, Eli Lilly and others.

Polaris market research has segmented the gout therapeutics market report based on drug class, disease condition, and region:

Gout Therapeutics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Urate Lowering Agents

Gout Therapeutics, Disease Condition Outlook (Revenue - USD Billion, 2019 - 2032)

  • Acute
  • Chronic

Gout Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gout Therapeutics Market Insights

  • 4.1. Gout Therapeutics Market - Industry Snapshot
  • 4.2. Gout Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of gout worldwide
      • 4.2.1.2. Continuous research and development activities
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Cost of treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Gout Therapeutics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Gout Therapeutics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gout Therapeutics, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs) by Region, 2019-2032 (USD Billion)
  • 5.4. Corticosteroids
    • 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
  • 5.5. Colchicine
    • 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2019-2032 (USD Billion)
  • 5.6. Urate Lowering Agents
    • 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2019-2032 (USD Billion)

6. Global Gout Therapeutics Market, by Disease Condition

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
  • 6.3. Acute
    • 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2019-2032 (USD Billion)
  • 6.4. Chronic
    • 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2019-2032 (USD Billion)

7. Global Gout Therapeutics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Gout Therapeutics Market - North America
    • 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
    • 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.3.3. Gout Therapeutics Market - U.S.
      • 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.3.4. Gout Therapeutics Market - Canada
      • 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.4. Gout Therapeutics Market - Europe
    • 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.3. Gout Therapeutics Market - UK
      • 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.4. Gout Therapeutics Market - France
      • 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.5. Gout Therapeutics Market - Germany
      • 7.4.5.1. Germany: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.6. Gout Therapeutics Market - Italy
      • 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.7. Gout Therapeutics Market - Spain
      • 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.8. Gout Therapeutics Market - Netherlands
      • 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.9. Gout Therapeutics Market - Russia
      • 7.4.9.1. Russia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.5. Gout Therapeutics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.3. Gout Therapeutics Market - China
      • 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.4. Gout Therapeutics Market - India
      • 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.5. Gout Therapeutics Market - Malaysia
      • 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.6. Gout Therapeutics Market - Japan
      • 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.7. Gout Therapeutics Market - Indonesia
      • 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.8. Gout Therapeutics Market - South Korea
      • 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.6. Gout Therapeutics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.3. Gout Therapeutics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.4. Gout Therapeutics Market - UAE
      • 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.5. Gout Therapeutics Market - Israel
      • 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.6. Gout Therapeutics Market - South Africa
      • 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.7. Gout Therapeutics Market - Latin America
    • 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.3. Gout Therapeutics Market - Mexico
      • 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.4. Gout Therapeutics Market - Brazil
      • 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.5. Gout Therapeutics Market - Argentina
      • 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Gout Therapeutics Market, by Drug Class, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Ablynx
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Antares Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Astellas Pharma
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. AstraZeneca
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Boehringer Ingelheim
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. CymaBay Therapeutics
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Eisai
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Eli Lilly
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. GlaxoSmithKline
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Horizon Pharma
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. JW Pharmaceutical
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. LG Life Sciences
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Merck
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Novartis
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Novo Nordisk
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Regeneron Pharmaceuticals
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Sandoz (a subsidiary of Novartis)
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Sanofi
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development
  • 9.19. Takeda Pharmaceuticals
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Development
  • 9.20. Teijin Pharma
    • 9.20.1. Company Overview
    • 9.20.2. Financial Performance
    • 9.20.3. Product Benchmarking
    • 9.20.4. Recent Development
  • 9.21. Vertex Pharmaceuticals
    • 9.21.1. Company Overview
    • 9.21.2. Financial Performance
    • 9.21.3. Product Benchmarking
    • 9.21.4. Recent Development